TNFSF10 and cancer: Finally, clinical differences in patient sensitivity to TRAIL have been found, and molecular typing of cancers is an aspect of TRAIL application that still needs to be explored, which may provide an important foundation for the future development of personalized TRAIL pathway-targeted therapies.